Ensysce Biosciences Announces Participation in Upcoming Investor Conferences
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Ensysce Biosciences (NASDAQ:ENSC) announced that management of recently acquired Cy Biopharma will participate in two upcoming investor conferences. The UBS Healthcare Therapeutics Conference fireside chat takes place in London on November 17, 2026, from 2:40–3:10 p.m. GMT (9:40–10:10 a.m. ET), with a live webcast available. The company presentation at the 38th Annual Piper Sandler Healthcare Conference takes place in New York on December 3, 2026, from 2:10–2:30 p.m. ET. Participants include James Morrison, Roger Sawhney and Prof. Richard Langford.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, CA / ACCESS Newswire / November 16, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage biotechnology company developing novel neuroplastogenic therapies beyond mood disorders, with an initial focus on CRPS (Complex Regional Pain Syndrome), today announced that management of the recently acquired Cy Biopharma Inc., James Morrison, Chief Executive Officer; Roger Sawhney, MD, Chief Financial Officer and Chief Business Officer; and Prof. Richard Langford, Chief Medical Officer, will participate in two upcoming investor conferences:
The UBS Healthcare Therapeutics Conference
Format: Fireside chat
Date: Tuesday, November 17, 2026
Time: 2:40-3:10 p.m. GMT (9:40-10:10 a.m. ET)
Location: London, U.K.
The 38th Annual Piper Sandler Healthcare Conference
Format: Company presentation
Date: Thursday, December 3, 2026
Time: 2:10-2:30 p.m. ET
Location: New York, N.Y.
A live webcast of the UBS fireside chat can be accessed here.
About Ensysce Biosciences
Ensysce Biosciences is a clinical-stage biotechnology company developing novel neuroplastogenic therapies using psychedelics that go beyond mood disorders and address the root cause of chronic pain through central nervous system modulation. The company is also developing a new class of highly novel opioids for the treatment of severe pain while minimizing the risk of both drug abuse and overdose. For more information, please visit www.ensysce.com.
About Cy Biopharma
Cy Biopharma is a clinical-stage biotechnology company developing novel neuroplastogenic therapies for severe chronic pain disorders. The company is advancing innovative treatments designed to address the underlying mechanisms of Complex Regional Pain Syndrome with the goal of delivering durable clinical benefit for patients with significant unmet medical need. For more information, please visit www.cybiopharma.com.
Forward-Looking Statements
Statements contained in this press release that are not purely historical may be deemed to be forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. Without limiting the foregoing, the use of words such as "may," "intends," "might," "will," "expect," "plan," "possible," "believe" and other similar expressions are intended to identify forward-looking statements. All forward-looking statements are based upon management's estimates and forecasts and reflect the current views, assumptions, expectations and opinions of the Company as of the date hereof. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expected, including (i) possible Nasdaq delisting; (ii) failure to obtain stockholder approval for the conversion of the Series C non-voting convertible preferred stock into shares of common stock of the combined company; (iii) risks related to the combined company's ability to manage its operating expenses and its expenses associated with the acquisition; (iv) unexpected costs, charges or expenses resulting from the acquisition; (v) potential adverse reactions or changes to business relationships resulting from the announcement or completion of the acquisition; (vi) the uncertainties associated with the combined company's product candidates, as well as risks associated with the clinical development and regulatory approval of product candidates, including potential delays in the commencement and completion of clinical trials, studies and evaluations; (vii) risks related to the inability of the combined company to obtain sufficient additional capital, including the continuation of government funding, to continue to advance these or other product candidates; (viii) failure to achieve the clinical trial milestone for the Milestone Closing; (ix) uncertainties in obtaining successful clinical results for product candidates and unexpected costs that may result therefrom; (x) risks related to the failure to realize any value from product candidates currently being developed and anticipated to be developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market; and (xi) risks associated with the possible failure to realize certain anticipated benefits of the acquisition, including with respect to future financial and operating results. These statements are also subject to risks and uncertainties described in Ensysce's most recent annual report on Form 10-K and quarterly report on Form 10-Q and in other filings that it makes with the U.S. Securities and Exchange Commission (the "SEC"), available at www.sec.gov. Any forward-looking statement speaks only as of the date on which it was made. Ensysce undertakes no obligation to publicly update or revise any forward-looking statement, except as required under applicable law.
Company Contact:
Prof. Richard Langford, CEO, Cy Biopharma
r.langford@cybiopharma.com
Investor Relations Contact:
Matt Osborne, LifeSci Advisors
mosborne@lifesciadvisors.com
SOURCE: Ensysce Biosciences
View the original press release on ACCESS Newswire